SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Passive Stake in Palisade Bio, Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a 9.99% beneficial ownership stake in Palisade Bio, Inc.'s common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
• The filing reports beneficial ownership of 471,906 shares of Palisade Bio, Inc. common stock, $0.01 par value.
• This ownership represents 9.99% of the company's common stock.
• The Reporting Persons hold shared voting power and shared dispositive power over all 471,906 shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Palisade Bio, Inc.
• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd is identified as the managing member of Armistice Capital, LLC.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a reputable investment firm, which can be viewed as a positive signal of confidence in the company, although it provides no operational or financial performance details.

Positives

• A significant institutional investor (Armistice Capital) and its principal (Steven Boyd) have disclosed a substantial passive stake, which can be interpreted as a vote of confidence in Palisade Bio, Inc.'s long-term prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, suggesting a stable, long-term investment intent.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Armistice Capital, LLC and Steven Boyd in Palisade Bio, Inc., a common occurrence in the financial markets where institutional investors acquire stakes in publicly traded companies. Such filings provide transparency regarding large ownership positions but do not typically offer insights into the issuer's operational industry trends or specific competitive landscape.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by Armistice Capital and Steven Boyd may be viewed positively by other shareholders, potentially signaling confidence in Palisade Bio, Inc.'s value proposition and attracting further investor interest.

Key Dates

Keywords

Palisade Bio Inc., Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, equity holding, SEC filing